Johnson & Johnson (JNJ) Q1 2026 Earnings
Johnson & Johnson reported Q1 2026 revenue of $24.1B (+9.9% YoY), beat analyst consensus of $23.6B by $447.3M. Diluted EPS came in at $2.70 (-2.5% YoY), beat the $2.68 consensus by $0.02. Johnson & Johnson reports across 2 business segments, led by Innovative Medicine and MedTech.
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Johnson & Johnson's Q1 2026 earnings report.
Johnson & Johnson (JNJ) reported Q1 2026 earnings on April 14, 2026 before market open.
Johnson & Johnson reported revenue of $24.1B and diluted EPS of $2.70 for Q1 2026.
Revenue beat the consensus estimate of $23.6B by $447.3M. EPS beat the consensus estimate of $2.68 by $0.02.
Compared to the same quarter a year prior, revenue grew 9.9% from $21.9B a year earlier and diluted EPS declined 2.5% from $2.77.
Johnson & Johnson reports across 2 business segments, led by Innovative Medicine and MedTech. Segment-level financials are available on the company's metrics pages.
You can read the 8-K earnings release (0000200406-26-000076) and the 10-Q periodic report (0000200406-26-000087) directly on SEC EDGAR. The filing index links above go to sec.gov.